Hot Investor Mandate 1: Evergreen Corporate VC Seeks Therapeutics in Phase I-II

5 May

A corporate venture fund located in Europe has an evergreen structure that allows flexibility in the investment approach and the possibility, when appropriate, to take a long-term perspective in the investments. The fund has an annual investment capacity of approximately €50m. Investments are typically around €10 million with reserves to follow, and the firm prefers to take above 10% ownership. The fund invests primarily in Europe and in the USA/Canada.

The fund invests exclusively in life sciences, focusing on pharmaceuticals. The firm typically prefers to invest at phase I/II but has also made investments at earlier phases of development. The firm is open to opportunities in all therapeutic areas and indications.

The fund is oriented towards opportunities in the US and Europe and will take the role of lead investor in Europe. In US the firm prefers to syndicate with well-established VC investors specialized in life sciences. The fund expects to be actively in communication with management and represented.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: